<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62035">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01861236</url>
  </required_header>
  <id_info>
    <org_study_id>000036</org_study_id>
    <nct_id>NCT01861236</nct_id>
  </id_info>
  <brief_title>Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina</brief_title>
  <acronym>FAST AR</acronym>
  <official_title>Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <authority>Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, observational study to collect and analyze data on patients with advanced
      hormone dependent prostate cancer treated with Firmagon® according to routine medical
      practice in Argentina
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Progression-free survival (PFS) failure rate (with failure defined as either prostate-specific antigen (PSA) failure, introduction of additional therapy related to prostate cancer, or death)</measure>
    <time_frame>During 3 years treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>The PFS failure rate will be estimated with time to PFS failure as dependent and adjusting for disease stage at baseline, baseline PSA, baseline testosterone (if available) and baseline serum Alkaline Phosphatase (s-ALP, if available)</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Advanced Hormone Dependent Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Advanced Prostate Cancer</arm_group_label>
    <description>Advanced Prostate Cancer that receive Firmagon therapy in the context of usual clinical practice</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Firmagon® (degarelix)</intervention_name>
    <description>Monthly subcutaneous injections</description>
    <arm_group_label>Advanced Prostate Cancer</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        200 patients with Advanced Prostate Cancer that receive Firmagon therapy in the context of
        usual clinical practice
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced Prostate Cancer patients to be treated with Firmagon in the context of usual
             clinical practice

          -  Written informed consent

        Exclusion Criteria:

          -  Contraindications to Firmagon

          -  Patients already on Firmagon therapy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Development Support</last_name>
    <email>DK0-Disclosure@ferring.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de Trauma y Emergencia Dr Federico Abete</name>
      <address>
        <city>Ingeniero Pablo Nogués</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 23, 2014</lastchanged_date>
  <firstreceived_date>May 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Androgens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
